Pretreatment with coixol restored the Bcl-2/Bax ratio by 2.2-fold (p < 0.001 vs. CML), an effect that was statistically comparable to that of NALC (p = 0.18 vs. coixol) and 4-PBA (p = 0.14 vs. coixol; Figure 5A). The gene discussed is BCL2; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.